Zinopin--the rationale for its use as a food supplement in Traveller's thrombosis and motion sickness.
Venous thrombo-embolism (VTE) has been associated with periods of prolonged immobility during air, sea and road travel. Motion sickness (MS) has also been reported during both long and short journeys. Current prophylactic therapies for both these indications are generally associated with side effects. Physiological profiles of Pycnogenol and Standardized Ginger Root Extract (SGRE) representing active constituents of Zinopin have been described and reviewed in relation to their activities involved in the patho-physiology of VTE (Traveller's Sickness) and MS and their safe use as food supplement, in traveller's thrombosis and motion sickness. The pathophysiology of VTE and MS is discussed in light of epidemiological data and risk factors associated with these conditions. Rationale of development of Zinopin and its mechanism of action are discussed based on physiological synergy of Pycnogenol and SGRE. Conclusions are made in light of preliminary clinical findings obtained in an open controlled clinical trial. Further clinical study on Zinopin on these lines is suggested.
The Lister Hospital, Chelsea Bridge Road, London, UK.
J H
JH
Scurr
O P
OP
Gulati
D019587:Dietary Supplements; D005419:Flavonoids / Q000008:administration & dosage / Q000627:therapeutic use*; D020939:Zingiber officinale; D006801:Humans; D009041:Motion Sickness / Q000517:prevention & control*; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D018517:Plant Roots; D013923:Thromboembolism / Q000517:prevention & control*; D014195:Travel
D005419:Flavonoids; D010936:Plant Extracts; C024070:pycnogenols